| |
|
|
INCHON, SOUTH KOREA - VaxGen, developer of an AIDS vaccine soon to exit phase 3 trials, will be acquiring a manufacturing plant in South Korea through a partnership with Celltrion, a South Korean venture partnership. Based in Brisbane, Calif., VaxGen will trade knowledge of human protein manufacturing for use of a manufacturing facility in Inchon, Celltrion's hometown. VaxGen will hold a 44% stake in the partnership. Celltrion aims to produce other biotech products at the facility in addition to VaxGen's vaccine. Celltrion also plans to develop a research facility for VaxGen in South San Francisco.
|
|
 |
Would you like information like this delivered to your email inbox? Subscribe to Tradeline Updates to keep abreast of the latest conference developments, industry news, best practices and more! Sign Up Now!
|
|
Printer Friendly Version
Send to a Friend
